Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

35.74 -0.01 (-0.03%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,059,860
Open	35.06
Bid (Size)	35.20 (100)
Ask (Size)	39.47 (100)
Prev. Close	35.75
Today's Range	35.00 - 36.50
52wk Range	16.79 - 42.20
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

May 11, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends ↗

May 08, 2026

NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what...

Via MarketBeat

Performance

YTD	+1.5%	+1.5%
1 Month	+10.0%	+10.0%
3 Month	+3.2%	+3.2%
6 Month	-5.2%	-5.2%
1 Year	+93.1%	+93.1%

More News

NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom ↗

May 07, 2026

Via Chartmill

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 07, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

March 23, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗

March 21, 2026

Via The Motley Fool

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

February 25, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

February 18, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

February 04, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

January 09, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

November 25, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Via The Motley Fool

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Via The Motley Fool

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Via The Motley Fool

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Via The Motley Fool

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Via The Motley Fool

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

November 05, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

October 30, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗

October 20, 2025

Via Benzinga

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?

Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.

What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?

NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?

The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market

What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?

The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 35.74

When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?

The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 05/21/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.